{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:19:06Z","timestamp":1777576746246,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Community Health"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diagnosing people living with chronic viral hepatitis is challenging due to the absence of symptoms as long as liver decompensated cirrhosis come out. The aim of this retrospective study was to evaluate the prevalence of HBV and\/or HCV infections in a non-selected population, hospitalised for SARS-CoV-2 infection in a tertiary care hospital in Northern Italy. During the study period 1,429 patients were admitted to hospital for SARS-CoV-2 infection, serologic tests for HBV and\/or HCV were available for 382 (27%) patients and 3 were excluded due to their previous known serologic status. Among 379 patients, 235 (62%) were male, median age was 70\u00a0years (range 21\u2013103), 360 (95%) were Caucasian. Among them, 372\/379 (98%) were screened for HBsAg, 320\/379 (84%) for HBcAb. HBsAg was positive in 2\/372 (0.5%, 95% CI 0.0006\u20130.02) patients (only in one HBV-DNA was performed that was negative), while HBcAb was found positive in 55\/320 (17%, 95% CI 0.13\u20130.22). Among 370\/379 (98%) patients screened for HCV, 11\/370 (3%, 95% CI 0.02\u20130.05) had positive HCV-Ab. Five out of 11 (45%) were tested for HCV-RNA that resulted positive in two patients (0.5%, 95% CI 0.0006\u20130.02). Considering this data, even though the screening was performed in only 27% of study population, a tailored screening in people with known risk factors for hepatitis might be preferable to universal screening in low prevalence areas. Also a prompt diagnostic workout should begin in case of clinical or laboratory suspicion of hepatitis and in those starting immunosuppressive treatments.<\/jats:p>","DOI":"10.1007\/s10900-022-01111-6","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T18:07:39Z","timestamp":1655834859000},"page":"800-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2"],"prefix":"10.1007","volume":"47","author":[{"given":"Silvia","family":"Dettori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Dentone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"1111_CR1","unstructured":"Global progress report on HIV, viral hepatitis and sexually transmitted infections. (2021). WHO Global report. Retrieved from https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"1111_CR2","unstructured":"Centers for Disease Control and Prevention. Nation center for HIV, viral hepatitis, STD and TB prevention. Retrieved from https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/index.htm."},{"issue":"3","key":"1111_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol, 2(3), 161\u2013176.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1111_CR4","unstructured":"Epicentro, dati SEIEVA 31 dicembre 2020. Istituto Superiore di Sanit\u00e0. Retrieved from https:\/\/www.epicentro.iss.it\/epatite\/dati-seieva."},{"key":"1111_CR5","unstructured":"CDA Foundation. Polaris Observatory. Retrieved from https:\/\/cdafound.org\/polaris\/."},{"key":"1111_CR6","unstructured":"Global health sector strategy on viral hepatitis 2016\u20132021. (2016). Towards ending viral hepatitis. World Health Organization. Retrieved from https:\/\/apps.who.int\/iris\/handle\/10665\/246177."},{"key":"1111_CR7","doi-asserted-by":"crossref","unstructured":"Razavi, H., Pawlotsky, J. M., Lazarus, J. V., et al. (2020) Global timing of hepatitis C virus elimination in high-income countries: an updated analysis. EASL Poster. Retrieved from https:\/\/www.natap.org\/2020\/EASL\/EASL_06.htm.","DOI":"10.1016\/S0168-8278(20)31138-7"},{"issue":"2","key":"1111_CR8","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.2196\/med20.2712","volume":"2","author":"P Fraccaro","year":"2013","unstructured":"Fraccaro, P., Pupella, V., Gazzarata, R., et al. (2013). The ligurian human immunodeficiency virus clinical network: A web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. Medicine 2.0, 2(2), e5.","journal-title":"Medicine 2.0"},{"issue":"RR-4","key":"1111_CR9","first-page":"1","volume":"61","author":"BD Smith","year":"2012","unstructured":"Smith, B. D., Morgan, R. L., Beckett, G. A., et al. (2012). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965. Morbidity and Mortality Weekly Report: Recommendations and Reports, 61(RR-4), 1\u201332.","journal-title":"Morbidity and Mortality Weekly Report: Recommendations and Reports"},{"key":"1111_CR10","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.epidem.2021.100442","volume":"34","author":"LA Kondili","year":"2021","unstructured":"Kondili, L. A., Andreoni, M., Alberti, A., et al. (2021). Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. Epidemics, 34, 100442.","journal-title":"Epidemics"},{"issue":"2","key":"1111_CR11","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1097\/QAI.0000000000002763","volume":"88","author":"G Lara-Paez","year":"2021","unstructured":"Lara-Paez, G., Zuazo, M., Blumenthal, J., Coyne, C. J., & Hoenigl, M. (2021). HIV and Hepatitis C virus screening in the emergency department and linkage to care during COVID-19: Challenges and solutions. Journal of Acquired Immune Deficiency Syndromes, 88(2), e14\u2013e16.","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"3","key":"1111_CR12","first-page":"201","volume":"57","author":"LA Kondili","year":"2021","unstructured":"Kondili, L. A., Aghemo, A., & Andreoni, M. (2021). Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: Need for a Regional programmatic approach on screening and linkage to care. Commentary. Ann Ist Super Sanita, 57(3), 201\u2013204.","journal-title":"Commentary. Ann Ist Super Sanita"},{"key":"1111_CR13","doi-asserted-by":"crossref","unstructured":"Marcellusi, A., Simonelli, C., Mennini, F. S., Kondili, L. A., PITER Collaborating Group available at http:\/\/www.progettopiter.it. (2022). Economic consequences of anti-HCV treatment of patients diagnosed through screening in Italy: A prospective modelling analysis.   Applied Health Economics and Health Policy,    20(1), 133\u2013143.","DOI":"10.1007\/s40258-021-00677-x"},{"issue":"2","key":"1111_CR14","first-page":"297","volume":"29","author":"LA Kondili","year":"2021","unstructured":"Kondili, L. A. (2021). How could Italy reach the HCV elimination by 2030? Le Infezioni in Medicina, 29(2), 297\u2013298.","journal-title":"Le Infezioni in Medicina"},{"issue":"9","key":"1111_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.dld.2020.05.040","volume":"52","author":"LA Kondili","year":"2020","unstructured":"Kondili, L. A., Marcellusi, A., Ryder, S., & Crax\u00ec, A. (2020). Will the COVID-19 pandemic affect HCV disease burden? Digestive and Liver Disease, 52(9), 947\u2013949.","journal-title":"Digestive and Liver Disease"},{"key":"1111_CR16","unstructured":"Testo della Legge 165 del 27\/05\/1991."},{"issue":"42","key":"1111_CR17","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.3748\/wjg.v27.i42.7271","volume":"27","author":"C Sagnelli","year":"2021","unstructured":"Sagnelli, C., Pisaturo, M., Curatolo, C., Codella, A. V., Coppola, N., & Sagnelli, E. (2021). Hepatitis B virus\/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic. World Journal of Gastroenterology, 27(42), 7271\u20137284.","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"1111_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/cid\/ciab405","volume":"74","author":"M Toy","year":"2022","unstructured":"Toy, M., Hutton, D., Harris, A. M., Nelson, N., Salomon, J. A., & So, S. (2022). Cost-effectiveness of 1-time universal screening for chronic hepatitis b infection in adults in the United States. Clinical Infectious Diseases, 74(2), 210\u2013217.","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"1111_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5114\/ceh.2019.87631","volume":"5","author":"M Paw\u0142owska","year":"2019","unstructured":"Paw\u0142owska, M., Flisiak, R., Gil, L., et al. (2019). Prophylaxis of hepatitis B virus (HBV) infection reactivation\u2014recommendations of the Working Group for prevention of HBV reactivation. Clinical and Experimental Hepatology, 5(3), 195\u2013202.","journal-title":"Clinical and Experimental Hepatology"},{"issue":"1","key":"1111_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo, R. P., Gish, R., & Falck-Ytter, Y. T. (2015). American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology, 148(1), 221-2443.e3.","journal-title":"Gastroenterology"},{"key":"1111_CR21","doi-asserted-by":"publisher","first-page":"706482","DOI":"10.3389\/fmed.2021.706482","volume":"8","author":"C Campbell","year":"2021","unstructured":"Campbell, C., Andersson, M. I., Ansari, M. A., et al. (2021). Risk of reactivation of HEPATITIS B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: A systematic review to inform risk assessment in the COVID-19 Era. Frontiers in Medicine, 8, 706482.","journal-title":"Frontiers in Medicine"},{"issue":"1","key":"1111_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jvh.13410","volume":"28","author":"S Rodr\u00edguez-Tajes","year":"2021","unstructured":"Rodr\u00edguez-Tajes, S., Miralpeix, A., Costa, J., et al. (2021). Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. Journal of Viral Hepatitis, 28(1), 89\u201394.","journal-title":"Journal of Viral Hepatitis"},{"issue":"36","key":"1111_CR23","doi-asserted-by":"publisher","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","volume":"21","author":"S Mori","year":"2015","unstructured":"Mori, S., & Fujiyama, S. (2015). Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World Journal of Gastroenterology, 21(36), 10274\u201310289.","journal-title":"World Journal of Gastroenterology"},{"issue":"12","key":"1111_CR24","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.3390\/jcm10122564","volume":"10","author":"C Stasi","year":"2021","unstructured":"Stasi, C., Tiengo, G., Sadalla, S., & Zignego, A. L. (2021). Treatment or prophylaxis against hepatitis B virus infection in patients with rheumatic disease undergoing immunosuppressive therapy: An update. Journal of Clinical Medicine, 10(12), 2564.","journal-title":"Journal of Clinical Medicine"},{"issue":"7","key":"1111_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/jama.2022.0335","volume":"327","author":"RT Gandhi","year":"2022","unstructured":"Gandhi, R. T., Malani, P. N., & Del Rio, C. (2022). COVID-19 Therapeutics for nonhospitalized patients. JAMA, 327(7), 617\u2013618.","journal-title":"JAMA"},{"issue":"1","key":"1111_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","volume":"74","author":"S Blach","year":"2021","unstructured":"Blach, S., Kondili, L. A., Aghemo, A., et al. (2021). Impact of COVID-19 on global HCV elimination efforts. Journal of Hepatology, 74(1), 31\u201336.","journal-title":"Journal of Hepatology"},{"issue":"12","key":"1111_CR27","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1046\/j.1440-1746.2000.0150121356.x","volume":"15","author":"I Merican","year":"2020","unstructured":"Merican, I., Guan, R., Amarapuka, D., et al. (2020). Chronic hepatitis B virus infection in Asian countries. Journal of Gastroenterology and Hepatology, 15(12), 1356\u20131361.","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"1111_CR28","unstructured":"The burden of viral hepatitis in the WHO Region of Africa. 2019. Retrieved from https:\/\/www.openaccessgovernment.org\/viral-hepatitis\/67856\/."}],"container-title":["Journal of Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-022-01111-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10900-022-01111-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-022-01111-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T07:12:48Z","timestamp":1663225968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10900-022-01111-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1007\/s10900-022-01111-6","relation":{},"ISSN":["0094-5145","1573-3610"],"issn-type":[{"value":"0094-5145","type":"print"},{"value":"1573-3610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"30 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Outside the submitted work, LT received grants for consultancies by ViiV Healthcare and Gilead Sciences. CD received grants for advisory boards sponsored by ViiV Healthcare and speaker invitations by Gilead Sciences, MB has received funding for scientific advisory boards, travel, and speaker honoraria from Angelini, Astellas, Bayer, BioM\u00e9rieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Shionogi, Tetraphase, Nabriva. ADB has received funding for scientific advisory boards, travel, and speaker honoraria from VIIV Healthcare, Gilead, Janssen, Abbvie, MSD. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Waived due to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Registry number 163\/2020, Liguria Region Ethics Committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}